Abstract |
Serum concentrations of tamoxifen, 4-OH-tamoxifen, N-desmethyltamoxifen, and metabolites E and Y were assayed to assess the variation of tamoxifen-metabolism during short-term and long-term endocrine treatment for breast cancer. Once steady-state was achieved, serum levels of tamoxifen and its metabolites in individual patients were stable in the short (10 weeks) and long term (over 7 years) (coefficient of variation [CV], 10-15%), but the variation between individuals (CV 50-70%) was high. Serum tamoxifen and N-desmethyltamoxifen levels were not correlated with indices of obesity. Thus this does not explain the large variation between individuals. In addition to the metabolites that were measured, 4-hydroxy-N-desmethyltamoxifen was tentatively identified in patients' serum. Overall, this study demonstrated that the metabolites of tamoxifen are stable (i.e. no metabolic tolerance) for up to 10 years of drug administration.
|
Authors | S M Langan-Fahey, D C Tormey, V C Jordan |
Journal | European journal of cancer (Oxford, England : 1990)
(Eur J Cancer)
Vol. 26
Issue 8
Pg. 883-8
( 1990)
ISSN: 0959-8049 [Print] England |
PMID | 2145931
(Publication Type: Journal Article)
|
Chemical References |
- Estrogen Antagonists
- Tamoxifen
- afimoxifene
- ICI 142269
- N-desmethyltamoxifen
|
Topics |
- Breast Neoplasms
(drug therapy)
- Drug Stability
- Estrogen Antagonists
(blood)
- Humans
- Tamoxifen
(administration & dosage, analogs & derivatives, blood, metabolism, therapeutic use)
- Time Factors
|